Shamim Faisal, Asghar Ali, Tauheed Saman, Yahya Muhammad
Department of Anaesthesiology, Aga Khan University Hospital, Karachi, Pakistan.
Saudi J Anaesth. 2017 Jan-Mar;11(1):21-25. doi: 10.4103/1658-354X.197367.
Radiofrequency ablation (RFA) is a minimally invasive technique of tumor destruction for patients with hepatic cancer who are not candidates for conventional therapy. The therapy required general anesthesia (GA) or sedation to ensure patient safety and comfort. The study is aimed to report and evaluate factors that influenced the periprocedural anesthetic management, drugs used, and complications during and immediately after RFA procedure for hepatocellular carcinoma.
For this retrospective study, we included 46 patients who underwent percutaneous RFA under GA or conscious sedation from January 2010 to June 2013 in Aga Khan University Hospital, Pakistan. The patients' characteristics, hepatic illness severity (Child-Pugh classification), anesthetic techniques, drugs, and complications of procedure were collected on a predesigned approved form. The data were assessed and summarized using descriptive statistics.
The majority of patients were female (57%) and mostly classified as American Society of Anesthesiologist III (65.2%). The preoperative hepatic illness severity in most patients was Child-Pugh Class A (76.10%). Thirty-eight patients (69.09%) had only single lesion and majority number of lesions were <3 cm (65.45). GA was the main anesthetic technique (87%) with laryngeal mask airway as an airway adjunct predominantly (70%). The mainly used anesthetic agents for hypnosis and analgesia were propofol and fentanyl, respectively. Pain was the only significant complaint in postoperative period but only in nine (19%) patients and mild in nature.
Percutaneous RFA is a safe treatment of hepatocellular cancer. The procedure required good anesthetic support in the form of sedation-analgesia or complete GA that ensures maximum patient comfort and technical success of the procedure.
射频消融术(RFA)是一种针对无法接受传统治疗的肝癌患者的微创肿瘤破坏技术。该治疗需要全身麻醉(GA)或镇静以确保患者的安全与舒适。本研究旨在报告并评估影响肝细胞癌RFA手术围手术期麻醉管理、所用药物以及术中及术后即刻并发症的因素。
对于这项回顾性研究,我们纳入了2010年1月至2013年6月在巴基斯坦阿迦汗大学医院接受GA或清醒镇静下经皮RFA的46例患者。通过预先设计并获批的表格收集患者的特征、肝病严重程度(Child-Pugh分级)、麻醉技术、药物及手术并发症。使用描述性统计对数据进行评估和总结。
大多数患者为女性(57%),多数被分类为美国麻醉医师协会III级(65.2%)。大多数患者术前肝病严重程度为Child-Pugh A级(76.10%)。38例患者(69.09%)仅有单个病灶,且大多数病灶<3 cm(65.45)。GA是主要的麻醉技术(87%),主要的气道辅助方式为喉罩通气(70%)。用于催眠和镇痛的主要麻醉药物分别为丙泊酚和芬太尼。疼痛是术后唯一显著的主诉,但仅9例(19%)患者有疼痛,且程度较轻。
经皮RFA是一种安全的肝细胞癌治疗方法。该手术需要以镇静镇痛或完全GA形式提供的良好麻醉支持,以确保患者最大程度的舒适和手术的技术成功。